* Osmotica Pharmaceuticals PLC OSMT.OQ OSMT.O is expected
to show a fall in quarterly revenue when it reports results on
August 16.
* The Bridgewater, New Jersey-based company is expected to
report a 7.9% decrease in revenue to $34.55 million from
$37.53 million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Osmotica
Pharmaceuticals PLC is for a loss of 14 cents per share. For the
same quarter last year, the company reported a loss of 22 cents
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Osmotica
Pharmaceuticals PLC is $7, about 40.1% above its last closing
price of $4.19.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.23 -0.23 -0.15 Beat 36.2
Dec. 31 2020 -0.28 -0.24 -0.88 Missed -271.8
Sep. 30 2020 -0.20 -0.20 -0.14 Beat 30
Jun. 30 2020 -0.12 -0.12 -0.22 Missed -76
Mar. -0.15 -0.14 -0.05 Beat 65.1
31 2020
Dec. 31 2019 -0.09 -0.06 -0.51 Missed -696.9
Sep. 30 2019 -0.23 -0.20 -2.15 Missed -961.7
Jun. 30 2019 -0.12 -0.14 0.02 Beat 113.8
This summary was machine generated August 13 at 21:20 GMT. All
figures in US dollars unless otherwise stated